$28.05
1.44%
Nasdaq, Nov 19, 04:00 pm EST. Closed.

Adaptive Biotechnologies Corp Stock News

Neutral
●
GlobeNewsWire
●
2 days ago
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies
Neutral
●
GlobeNewsWire
●
15 days ago
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) --  Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026. “Adaptive achieved total company pr...
Neutral
●
GlobeNewsWire
●
about 2 months ago
SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annu...
Neutral
●
GlobeNewsWire
●
2 months ago
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of th...
Neutral
●
GeekWire
●
3 months ago
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
Neutral
●
GlobeNewsWire
●
4 months ago
SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today